PEPCID RPD Drug Patent Profile

Which patents cover Pepcid Rpd, and when can generic versions of Pepcid Rpd launch?

Pepcid Rpd is a drug marketed by Merck and is included in one NDA.

The generic ingredient in PEPCID RPD is famotidine. There are eighteen drug master file entries for this compound. One hundred and forty-four suppliers are listed for this compound. Additional details are available on the famotidine profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Pepcid Rpd

A generic version of PEPCID RPD was approved as famotidine by FRESENIUS KABI USA on April 16^th, 2001.

Summary for PEPCID RPD

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	83
Clinical Trials:	35
DailyMed Link:	PEPCID RPD at DailyMed

Recent Clinical Trials for PEPCID RPD

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Ohio State University Comprehensive Cancer Center	Phase 2/Phase 3
Leidos Life Sciences	Phase 2
United States Department of Defense	Phase 2

See all PEPCID RPD clinical trials

US Patents and Regulatory Information for PEPCID RPD

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Merck	PEPCID RPD	famotidine	TABLET, ORALLY DISINTEGRATING;ORAL	020752-001	May 28, 1998		DISCN	No	No
Merck	PEPCID RPD	famotidine	TABLET, ORALLY DISINTEGRATING;ORAL	020752-002	May 28, 1998		DISCN	No	No

Expired US Patents for PEPCID RPD

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Merck	PEPCID RPD	famotidine	TABLET, ORALLY DISINTEGRATING;ORAL	020752-002	May 28, 1998
Merck	PEPCID RPD	famotidine	TABLET, ORALLY DISINTEGRATING;ORAL	020752-001	May 28, 1998
Merck	PEPCID RPD	famotidine	TABLET, ORALLY DISINTEGRATING;ORAL	020752-002	May 28, 1998
Merck	PEPCID RPD	famotidine	TABLET, ORALLY DISINTEGRATING;ORAL	020752-002	May 28, 1998
Merck	PEPCID RPD	famotidine	TABLET, ORALLY DISINTEGRATING;ORAL	020752-001	May 28, 1998
Merck	PEPCID RPD	famotidine	TABLET, ORALLY DISINTEGRATING;ORAL	020752-001	May 28, 1998

International Patents for PEPCID RPD

See the table below for patents covering PEPCID RPD around the world.

Country	Patent Number	Title	Estimated Expiration
Denmark	157132
Luxembourg	78259
Belgium	859291
U.S.S.R.	876056	METHOD OF PRODUCING GUANIDINOTHIAZOLE COMPOUNDS
Australia	2882577
Australia	5597580
Spain	8103070

PEPCID RPD Market Analysis and Financial Projection Experimental

Market Dynamics and Financial Trajectory for PEPCID RPD (Famotidine)

Overview of PEPCID RPD (Famotidine)

PEPCID RPD, commonly known by its generic name famotidine, is a histamine H2 receptor antagonist used to treat various gastrointestinal conditions, including duodenal ulcers, benign gastric ulcers, gastroesophageal reflux disease (GERD), and Zollinger-Ellison syndrome[2][3].

Market Dynamics

Increasing Prevalence of Gastrointestinal Diseases

The global market for GERD drugs and devices, which includes famotidine, is driven by the increasing prevalence of gastrointestinal diseases. The rising incidence of GERD, particularly among the younger generation due to changing lifestyles and increased consumption of fast food, alcohol, and aerated drinks, contributes significantly to the market growth[1].

Growing Geriatric Population

The geriatric population is a key demographic driving the demand for famotidine and other GERD treatments. Older adults are more prone to gastrointestinal issues, and the rise in this population segment is expected to boost the revenue growth of the GERD drugs and devices market[1].

Self-Medication and Over-the-Counter Demand

There is a growing trend towards self-medication and the use of over-the-counter (OTC) medications for gastrointestinal disorders. Famotidine, available in both prescription and OTC forms, benefits from this trend, as patients increasingly seek convenient and accessible treatments for heartburn and other GERD symptoms[1].

Advances in Diagnostic and Therapeutic Technologies

The market is also influenced by advancements in diagnostic and therapeutic technologies. Devices such as the Bravo Reflux Testing System and the Digitrapper Reflux Testing System, which are used in conjunction with medications like famotidine, are becoming more prevalent. These technologies enhance the diagnosis and treatment of GERD, further driving market growth[1].

Regional Market Trends

The Asia Pacific region is projected to register the fastest revenue CAGR in the global GERD drugs and devices market. This growth is attributed to the increasing prevalence of gastrointestinal diseases, rising volumes of diagnostic and surgical procedures, and a growing preference for minimally invasive surgeries in this region[1].

Financial Trajectory

Market Size and Growth

The global GERD drugs and devices market, which includes famotidine, was valued at USD 5.21 billion in 2020 and is expected to reach USD 6.28 billion by 2028, growing at a CAGR of 2.3% during the forecast period of 2021-2028[1].

Revenue Segmentation

• Drug Type: The antacids segment, which includes famotidine, dominated the market in terms of revenue share in 2020. This is due to the high demand for over-the-counter and generic medications for gastrointestinal disorders[1].
• Route of Administration: Famotidine is available in both oral and parenteral forms, with oral administration being the most common route. The oral segment is expected to continue driving revenue due to its convenience and widespread use[1].

Regional Revenue Contribution

• Asia Pacific: This region is expected to register the fastest revenue CAGR due to the increasing prevalence of GERD and other gastrointestinal diseases, along with a growing demand for diagnostic and therapeutic solutions[1].
• North America and Europe: These regions also contribute significantly to the market revenue, driven by a high incidence of GERD and a well-established healthcare infrastructure.

Competitive Landscape

The market for GERD drugs and devices is competitive, with several major companies involved. For famotidine, the competition includes other H2 receptor antagonists and proton pump inhibitors (PPIs). However, famotidine's efficacy, safety profile, and availability in both prescription and OTC forms help it maintain a strong market position[1].

Key Takeaways

• The global GERD drugs and devices market, including famotidine, is expected to grow at a CAGR of 2.3% from 2021 to 2028.
• The antacids segment, which includes famotidine, dominated the market in terms of revenue share in 2020.
• The Asia Pacific region is projected to register the fastest revenue CAGR.
• Increasing prevalence of gastrointestinal diseases, growing geriatric population, and rising trend of self-medication are key drivers of market growth.
• Advances in diagnostic and therapeutic technologies also contribute to the market's financial trajectory.

FAQs

What is the primary use of PEPCID RPD (Famotidine)?

PEPCID RPD, or famotidine, is primarily used to treat conditions such as duodenal ulcers, benign gastric ulcers, gastroesophageal reflux disease (GERD), and Zollinger-Ellison syndrome.

What is the expected market size of the GERD drugs and devices market by 2028?

The global GERD drugs and devices market is expected to reach USD 6.28 billion by 2028[1].

Which region is expected to grow the fastest in the GERD drugs and devices market?

The Asia Pacific region is projected to register the fastest revenue CAGR in the global GERD drugs and devices market[1].

What are the key factors driving the growth of the GERD drugs and devices market?

Key factors include the increasing geriatric population, rising prevalence of gastrointestinal diseases, changing lifestyles, and the growing trend of self-medication and demand for over-the-counter medications[1].

How does famotidine compare to other treatments for GERD?

Famotidine is a histamine H2 receptor antagonist that is effective in reducing gastric acid secretion and is often used in conjunction with other treatments. It is known for its safety profile and is available in both prescription and OTC forms, making it a popular choice for managing GERD symptoms[2][3].

Sources

1. Emergen Research: GERD Drugs and Devices Market Size to Reach USD 6.28 Billion in 2028 Growing at a CAGR of 2.3% - Emergen Research.
2. DrugBank: Famotidine: Uses, Interactions, Mechanism of Action.
3. FDA: PEPCID - accessdata.fda.gov.
4. Cognitive Market Research: Famotidine Market Report 2024 (Global Edition).